Corbus Pharmaceuticals Holdings, Inc.

CRBP Healthcare Biotechnology

In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.52 0.19 +4.39%
Market cap
$83.8M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
3/9
Altman Z
−4.15
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.71 7.92 8.07 6.31
Net Debt/EBITDA
3.24 5.63 7.25 4.27
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.53) (1.37) (1.20) (1.26)
Book value per Share
5.27 6.75 11.08 7.49
Free Cash Flow
(29.63) (25.58) (15.93) (15.55)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates